ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Valeant Increases Bid For Allergan

by Marc S. Reisch
June 2, 2014 | APPEARED IN VOLUME 92, ISSUE 22

Valeant Pharmaceuticals has sweetened its offer to buy specialty drugmaker Allergan to $50 billion in an effort to persuade Allergan’s board to agree to the deal. Like Valeant’s original $47 billion offer at the end of April, the new bid is backed by activist investor William A. Ackman. Separately, Valeant said it will sell a portfolio of dermatology drugs to Nestlé for $1.4 billion. The sale would remove some regulatory concerns over Valeant’s combination with Allergan, which makes the wrinkle-reducing drug Botox.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment